 LEXINGTON, Mass., March 10, 2021 GLOBE NEWSWIRE -- Agenus Inc. NASDAQ: AGEN, an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines designed to activate immune response to cancers and infections, today announced that two abstracts on AGEN1181, Agenus Fc-enhanced next-generation anti-CTLA-4 antibody, were accepted for presentation at the American Association for Cancer Research AACR Annual Meeting from April 10 - 15, 2021. 